To the Editor: I read with great interest the recent article by Zhang et al. (2012a) . Interestingly recent data suggest that galangin may influence carcinogenesis in a number of systemic tumors besides melanomas.
For instance, galangin activates the caspase 8/t-Bid mitochondrial pathway in hepatocellular carcinomas (Zhang et al. 2012b) . Simultaneously there is an increase in Bid disintegration resulting in increased tBid. Simultaneously, galangin administration results in increased release of cytochrome-c into the cytoplasm by virtue of enhanced translocation of Bax to mitochondria in the neoplastic cells (Zhang et al. 2010) . As a result, galangin results in accentuated apoptosis in these tumors. This enhanced galangin mediated apoptosis is inhibited by up regulation of Bcl-2.
Similarly, galangin modulates glutathione S-transferase P function. As a consequence, it enhances apoptosis in gastric malignancies. Simultaneously, it also affects ubiquitin carboxy-terminal hydrolase isozyme function thus further accentuating apoptosis in gastric neoplastic cells (Kim et al. 2012) . Modulation of the above enzymes results in accentuated expression of JNK as well as ERK 1/2. Simultaneously, there is an increase in the cleavage of poly (ADP-ribose) polymerase.
Similar, when administered to imatinib sensitive leukemias, galangin increases the sensitivities of these hematological malignancies. It also helps overcome imatinib resistance in imatinib resistant Bcr-Abl expressing leukemias (Tolomeo et al. 2008) . A decline in Bcl-2 level is seen following galangin administration. Similarly, a decline in cdk1 and cdk4 levels accompanies galangin administration. As a result of this enhanced sensitivity there is an increase in G0/G1 phase cells. Similarly, tumor growth is attenuated in animal models with Ehrlich ascites carcinoma following the administration of galangin (Jaiswal et al. 2012) . The above examples clearly illustrate the significant role of galangin in the need for oncology and further studies in this regard.
